Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

426

HTML

2842

Tables (1-7)

458

Sum=3726

May 16, 2010 (publication date) through Feb 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Endosc. May 16, 2010; 2(5): 165-178
Published online May 16, 2010. doi: 10.4253/wjge.v2.i5.165

Table 6 Pharmacologic agents evaluated for potential reduction/prevention of post-ERCP pancreatitis

Pharmacologic agent	RCT showed benefit
Allopurinol	Yes
Cephtazidime	Yes
Diclofenac	Yes
Gabexate	Yes
Glyceryl trinitrate	Yes
Hydrocortisone	Yes
Indomethacin	Yes
Interleukin-10 (IL-10)	Yes
Nafamostat mesylate	Yes
Octreotide	Yes
Somatostatin	Yes
Ulinastatin	Yes
Anticholinergic drugs	No
Aprotinin	No
Botulinum toxin	No
Calcitonin	No
Epinephrine	No
Fresh frozen plazma	No
Glucagon	No
H-2 Blocker	No
Heparin	No
Lidocaine	No
Methylprednisolone	No
N-aceytyl cysteine (NAC)	No
Natural beta-carotene	No
Nifedipine	No
Nitroglycerin	No
Parenteral nutrition	No
Pentoxifylline	No
Prednisone	No
Recombinant PAF acetylhydrolase (rPAF-AH)	No
Selenium	No
Semapimod	No

Citation: Woods KE, Willingham FF. Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review. World J Gastrointest Endosc 2010; 2(5): 165-178
URL: https://www.wjgnet.com/1948-5190/full/v2/i5/165.htm
DOI: https://dx.doi.org/10.4253/wjge.v2.i5.165